Top

Published in:

Open Access 01-12-2016 | Commentary

Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial

Author: Sanjay Kalra

Published in: Diabetes Therapy | Issue 4/2016

Abstract

This commentary analyzes the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which has reported the cardiovascular benefits of liraglutide. It places the results of this seminal trial in the context of the evolution of diabetes care, compares them with other recently published cardiovascular outcome trials, and suggests novel mechanisms to explain the benefits and properties of liraglutide. The editorial discusses the potential impact that LEADER will have on the prevention and management of diabetes and its vascular complications.

Baruah MP, Kalra B, Kalra S. Patient centred approach in endocrinology: from introspection to action. Indian J Endocrinol Metab. 2012;16(5):679.CrossRefPubMedPubMedCentral

Chinenye S, Ogbera AO, Kalra S. Patient-centered care in diabetology: Sub-Saharan African perspectives. Afr J Diabetes Med. 2014;22(1):5–8.

Kalra S, Megallaa MH, Jawad F. Patient-centered care in diabetology: from eminence-based, to evidence-based, to end user-based medicine. Indian J Endocrinol Metab. 2012;16(6):871.CrossRefPubMedPubMedCentral

John M, Unnikrishnan AG, Kalra S, Nair T. Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development? Indian Heart J. 2016;68(4):564–71.CrossRefPubMed

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.CrossRefPubMed

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.CrossRefPubMed

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.CrossRefPubMed

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.CrossRefPubMed

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.CrossRefPubMed

10.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr P-M, Lange M, Frandsen KB, Rabol R, Buse JB. Design of DEVOTE (trial comparing cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events)—DEVOTE 1. Am Heart J. 2016;17(179):175–83.CrossRef

11.

Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diabetes Vasc Dis Res. 2013;10(4):289–301.CrossRef

12.

Vaccaro O, Masulli M, Bonora E, Del Prato S, Nicolucci A, Rivellese AA, Riccardi G;, TOSCA.IT Study Group. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care. 2012;35(12):e82–e82.CrossRefPubMedPubMedCentral

13.

Kalra S, Jacob JJ, Gupta Y. Newer antidiabetic drugs and calorie restriction mimicry. Indian J Endocr Metab. 2016;20:142–6.CrossRef

14.

UK Prospective Diabetes Study. UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352(9131):837–53.CrossRef

15.

Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63:3346–58.CrossRefPubMed

16.

Miao XY, Gu ZY, Liu P, Hu Y, Li L, Gong YP, et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides. 2013;39:71–9.CrossRefPubMed

17.

Festi D, Villanova N, Colecchia A. Risk factors for gallstone formation during weight loss. Clin Gastroenterol Hepatol. 2015;13(3):613.CrossRefPubMed

18.

Keller J, Trautmann ME, Haber H, San Tham L, Hunt T, Mace K, Linnebjerg H. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179(1):77–83.CrossRefPubMed

19.

Johansson K, Sundström J, Marcus C, Hemmingsson E, Neovius M. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obes. 2014;38(2):279–84.CrossRef

20.

McKenna LA, Drummond RS, Drummond S, Talwar D, Lean ME. Seeing double: the low-carb diet. Br Med J. 2013;2013(346):f2563.CrossRef

21.

Avogaro A, Fadine GP, Sesti G, Bonora E, Del Prato S. continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol. 2016;15:111.CrossRefPubMedPubMedCentral

22.

Kalra S. One small step for empagliflozin, one giant leap for diabetology. Diabetes Ther. 2015;6(4):405–9.CrossRefPubMedPubMedCentral

23.

Kalra S, Jain A, Ved J, Unnikrishnan AG. Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect. Ind J Endocr Metab. [cited 2016 Aug 31]. http://www.ijem.in/preprintarticle.asp?id=183826. Accessed 31 Aug 2016 (Epub ahead of print).

24.

Control TD, Group CT. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol. 1995;75(14):894–903.CrossRef

25.

Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, Khurmi NS, Mentz RJ, Oulhaj A, Buse JB, Chan JC. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J. 2016;30(174):103–10.CrossRef

26.

Eli Lilly and Company. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). clinicaltrials.gov. Bethesda: National Library of Medicine; 2011–2013. NLM Identifier NCT01394952.

Title: Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Author: Sanjay Kalra
Publication date: 01-12-2016
Publisher: Springer Healthcare
Published in: Diabetes Therapy / Issue 4/2016
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-016-0197-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

A Practical Approach to Glucose Abnormalities in Cystic Fibrosis

Letter to the Editor Regarding: Patterns and Impact of Hypoglycemia, Hyperglycemia, and Glucose Variability on Inpatients with Insulin-Treated Cystic Fibrosis-Related Diabetes

Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study

Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective

Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis

Medication Adherence Contributes to an Improved Quality of Life in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page